Your browser doesn't support javascript.
loading
Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial.
Hartmann, Jessica A; Schmidt, Stefanie J; McGorry, Patrick D; Berger, Maximus; Berger, Gregor E; Chen, Eric Y H; de Haan, Lieuwe; Hickie, Ian B; Lavoie, Suzie; Markulev, Connie; Mossaheb, Nilufar; Nieman, Dorien H; Nordentoft, Merete; Polari, Andrea; Riecher-Rössler, Anita; Schäfer, Miriam R; Schlögelhofer, Monika; Smesny, Stefan; Thompson, Andrew; Verma, Swapna K; Yuen, Hok Pan; Yung, Alison R; Amminger, G Paul; Nelson, Barnaby.
Afiliação
  • Hartmann JA; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia. Electronic address: Jessica.hartmann@orygen.org.au.
  • Schmidt SJ; Department of Clinical Psychology and Psychotherapy, University of Bern, Switzerland.
  • McGorry PD; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Berger M; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Berger GE; Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, University of Zurich, CH-8032, Zurich, Switzerland.
  • Chen EYH; Department of Psychiatry, University of Hong Kong, Hong Kong, China.
  • de Haan L; Department of Psychiatry, Academic Medical Center, Amsterdam, the Netherlands.
  • Hickie IB; Brain and Mind Research Institute, University of Sydney, Sydney, Australia.
  • Lavoie S; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Markulev C; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Mossaheb N; Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University of Vienna, Vienna, Austria.
  • Nieman DH; Department of Psychiatry, Academic Medical Center, Amsterdam, the Netherlands.
  • Nordentoft M; CORE-Copenhagen Research Centre for Mental Health, Mental Health Centre Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Polari A; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Riecher-Rössler A; University of Basel, Basel, Switzerland.
  • Schäfer MR; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Schlögelhofer M; Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University of Vienna, Vienna, Austria; Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.
  • Smesny S; Department of Psychiatry, Jena University Hospital, Jena, Germany.
  • Thompson A; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia; Warwick Medical School, University of Warwick, Coventry, UK.
  • Verma SK; Institute of Mental Health, Singapore.
  • Yuen HP; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Yung AR; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Amminger GP; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
  • Nelson B; Orygen, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
Behav Res Ther ; 124: 103527, 2020 01.
Article em En | MEDLINE | ID: mdl-31790853
ABSTRACT
The Ultra-High Risk (UHR) for psychosis group is known to be heterogeneous with diverse outcomes. This study aimed to 1. Identify subclasses of UHR individuals based on trajectories of symptomatic and functional change over time, 2. Identify predictors of these trajectories. A sample of 304 UHR individuals participating in the Neurapro trial were followed over an average of 40 months. All participants received cognitive-behavioural case management (CBCM). Symptomatic and functional profiles were investigated using latent class growth analysis. Multinomial regression was employed to investigate predictors of classes. Identified trajectories showed mostly parallel slopes (i.e. improving symptoms/functioning over time), which were primarily distinct regarding the severity of symptomatology/level of functioning at baseline (i.e. the intercept). Higher symptomatic/lower functioning classes were predicted by higher substance use, older age, female gender, and lower cognitive functioning. No divergent trajectories were identified as all classes improved over time. This may reflect effective treatment through CBCM, natural illness course, or effective engagement with mental health services. Nonetheless, classes highest in symptoms/lowest in functioning still showed considerable impairment during follow-up, highlighting the need for targeted intervention in these subgroups. The study emphasizes the need for more clinical attention directed towards UHR patients being female or using substances.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article